Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients
Payers commonly emphasize acceptable cost-effectiveness, but strong clinical evidence for many variants and comparable costs to standard tests are likely to drive positive reimbursement decisions for WGS.
Authors
- Maarten J. IJzerman (ORCID: https://orcid.org/0000-0001-5788-5805)
- Martin Vu (ORCID: https://orcid.org/0000-0001-5918-1692)
- Koen Degeling (ORCID: https://orcid.org/0000-0001-7487-2491)
- David Westerman (ORCID: https://orcid.org/0000-0002-9288-9817)
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Melbourne Health (AU)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Journal of Cancer Policy
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1016/j.jcpo.2024.100501
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Illumina
- University of Melbourne